Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 56

Sort by

Sort Order Select

Journal Articles

Pharmacologic Normalization of Altered Transcriptome of SF3B1 Mutant Myeloid Neoplasia

Blood (2019) 134 (Supplement_1): 564.

https://doi.org/10.1182/blood-2019-129189

Published: 2019

Journal Articles

Updated Results from the Venetoclax (Ven) in Combination with Idasanutlin (Idasa) Arm of a Phase 1b Trial in Elderly Patients (Pts) with Relapsed or Refractory (R/R) AML Ineligible for Cytotoxic Chemotherapy

Blood (2019) 134 (Supplement_1): 229.

https://doi.org/10.1182/blood-2019-123711

Published: 2019

Journal Articles

CUL1: Novel Therapeutic Target in Myeloid Neoplasms Harboring -7/Del(7q)

Blood (2019) 134 (Supplement_1): 1281.

https://doi.org/10.1182/blood-2019-129196

Published: 2019

Journal Articles

A Pooled Analysis of Relapsed/Refractory Diffuse Large B-Cell Lymphoma Patients Treated with the Dual PI3K and HDAC Inhibitor Fimepinostat (CUDC-907), Including Patients with MYC-Altered Disease

Daniel J. Landsburg, MD, Radhakrishnan Ramchandren, MD, Petronella J Lugtenburg, MD PhD, Kevin R. Kelly, MD PhD, Anas Younes, MD, Robert Gharavi, PharmD, David P. Tuck, MD, Stefan Klaus Barta, MD MRCP, MS

Blood (2018) 132 (Supplement 1): 4184.

https://doi.org/10.1182/blood-2018-99-112527

Published: 2018

Journal Articles

Exploring Disease Biology in Hispanic Versus Non-Hispanic Patients with Diffuse Large B-Cell Lymphoma (DLBCL) to Explain Survival Disparities

Sikander Ailawadhi, Alvaro J. Alencar, MD, Madiha Iqbal, MBBS, Prachi Jani, MD, Salman Ahmed, MD, Aditya Mehta, Ruqin Chen, MD, Leyla Bojanini, MD, Moises Harari Turquie, MD, Kevin R Kelly, MD PhD, Prakash Vishnu, MD, Vivek Roy, MD, Anshika Singh, Abuzar Asif, Shishir David, Imran Siddiqi, MD PhD, Asher A. Chanan-Khan, MD, Taimur Sher, MD

Blood (2018) 132 (Supplement 1): 4867.

https://doi.org/10.1182/blood-2018-99-119494

Published: 2018

Journal Articles

Development of a Novel Class of Agents Targeting the RNA-Splicing Machinery in Myeloid Malignancies

Blood (2018) 132 (Supplement 1): 211.

https://doi.org/10.1182/blood-2018-99-116411

Published: 2018

Journal Articles

Activation of Autophagy in Models of SF3B1 Mutant MDS

Blood (2017) 130 (Supplement 1): 4230.

https://doi.org/10.1182/blood.V130.Suppl_1.4230.4230

Published: 2017

Journal Articles

Preliminary Results from a Phase Ib Study Evaluating BCL-2 Inhibitor Venetoclax in Combination with MEK Inhibitor Cobimetinib or MDM2 Inhibitor Idasanutlin in Patients with Relapsed or Refractory (R/R) AML

Naval Daver, MD, Daniel A. Pollyea, MD, Karen W.L. Yee, MD, Pierre Fenaux, MD PhD, Joseph M. Brandwein, MD FRCPC, Norbert Vey, Giovanni Martinelli, Kevin R Kelly, MD PhD, Gail J. Roboz, MD, Jacqueline S. Garcia, Arnaud Pigneux, MD PhD, Smita Kshirsagar, Monique Dail, Jue Wang, Mehrdad Mobasher, Lin-Chi Chen, Wan-Jen Hong, Marina Konopleva, MD PhD, Michael Andreeff, MD PhD

Blood (2017) 130 (Supplement 1): 813.

https://doi.org/10.1182/blood.V130.Suppl_1.813.813

Published: 2017

Journal Articles

Racial Differences in Disease Characteristics: Understanding Multiple Myeloma in Hispanics

Tania Jain, MD, Rafael Fonseca, MD, Ruqin Chen, MD, Raj Patel, MD, Prachi Jani, MD, Veronica Gonzalez De La Calle, MD, Zahara Meghji, James E. Hoffman, MD, Alvaro J. Alencar, MD, Kevin R Kelly, MD PhD, Vivek Roy, MD, Taimur Sher, MD, Asher A. Chanan-Khan, MD, Sikander Ailawadhi

Blood (2017) 130 (Supplement 1): 864.

https://doi.org/10.1182/blood.V130.Suppl_1.864.864

Published: 2017

Journal Articles

The Presence of Philadelphia Chromosome Does Not Confer Poor Prognosis in Adult Pre-B Acute Lymphoblastic Leukemia in the Tyrosine Kinase Inhibitor Era - a Surveillance, Epidemiology, and End Results Database Analysis

Igwe John Igwe, Dongyun Yang, PhD, Merchant Akil, Noah Merin, George Yaghmour, Kevin R Kelly, MD PhD, Giridharan Ramsingh, MD

Blood (2017) 130 (Supplement 1): 2567.

https://doi.org/10.1182/blood.V130.Suppl_1.2567.2567

Published: 2017

Journal Articles

Oncolytic Reovirus Sensitizes Multiple Myeloma Cells to Anti-PD-L1 Therapy

Kevin R Kelly, MD PhD, Claudia M Espitia, Weiguo Zhao, Kaijin Wu, Valeria Visconte, PhD, Faiz Anwer, MD, Christine M Calton, PhD, Jennifer S. Carew, PhD, Steffan T. Nawrocki, PhD

Blood (2017) 130 (Supplement 1): 3137.

https://doi.org/10.1182/blood.V130.Suppl_1.3137.3137

Published: 2017

Journal Articles

Minimal Residual Disease (MRD) Assessment By Multiparametric Flow Cytometry Is Prognostic for Progression-Free Survival in Phase 1/1b Relapsed/Refractory Acute Myeloid Leukemia (AML) Patients Treated with Idasanutlin MDM2 Antagonist

Benjamin Lanza, Giovanni Martinelli, Karen W.L. Yee, MD, Lori Jukofsky, Bernhard Reis, PhD, Steven Blotner, PhD, Mark W. Drummond, PhDMD, Norbert Vey, MD PhD, Karen Seiter, MD, Michael J. Dickinson, MBBS, FRACP, FRCPA, Kevin R. Kelly, MD PhD, Margaret Kasner, MD, Michel Theron, PhD, Jeffrey M. Venstrom, Steven Middleton, PhD, Lin-Chi Chen, MD PhD, Nelson Kinnersley, Gwen Nichols, MD, William E. Pierceall, PhD

Blood (2016) 128 (22): 2843.

https://doi.org/10.1182/blood.V128.22.2843.2843

Published: 2016

Journal Articles

Persistent Racial/Ethnic Disparities in Outcomes for Multiple Myeloma: A SEER-Database Update

Kevin R. Kelly, MD PhD, Dongyun Yang, Mayank Sharma, MBBS, Vivek Roy, MD, Asher A. Chanan-Khan, MD, Sikander Ailawadhi, MD

Blood (2016) 128 (22): 1191.

https://doi.org/10.1182/blood.V128.22.1191.1191

Published: 2016

Journal Articles

Racial/Ethnic Disparities in NK/T-Cell Non-Hodgkin Lymphomas in the US: A SEER Analysis

Irene Kang, MD, Dongyun Yang, Mi Hee Park, MD, Ann Mohrbacher, MD, Anil Tulpule, MD, Imran N Siddiqi, MD PhD, Sikander Ailawadhi, MD, Kevin R. Kelly, MD PhD

Blood (2016) 128 (22): 3612.

https://doi.org/10.1182/blood.V128.22.3612.3612

Published: 2016

Journal Articles

A Novel Oncolytic Reovirus Immune Priming Strategy Dramatically Enhances the Efficacy of Anti-PD-L1 Antibody Therapy Against Multiple Myeloma

Kevin R. Kelly, MD PhD, Claudia M. Espitia, Weiguo Zhao, Valeria Visconte, PhD, Matt Coffey, Jennifer S. Carew, PhD, Steffan T. Nawrocki, PhD

Blood (2016) 128 (22): 3960.

https://doi.org/10.1182/blood.V128.22.3960.3960

Published: 2016

Journal Articles

Targeting Autophagy in Myelodysplastic Syndromes

Valeria Visconte, PhD, Steffan T. Nawrocki, PhD, Bartlomiej P Przychodzen, MSc, Kevin R. Kelly, MD PhD, Mei Yin, Yvonne Parker, Michael J. Clemente, M.S., John Barnard, PhD, Anjali S. Advani, MD, Hetty E. Carraway, MD MBA, Mikkael A. Sekeres, MD MS, Daniel Lindner, Heesun J Rogers, MD PhD, Jaroslaw P Maciejewski, MD PhD FACP, Jennifer S. Carew, PhD

Blood (2016) 128 (22): 4295.

https://doi.org/10.1182/blood.V128.22.4295.4295

Published: 2016

Journal Articles

Genetic and Epigenetic Defects in the Autophagy Machinery in Myelodysplastic Syndromes

Valeria Visconte, PhD, Bartlomiej P Przychodzen, MSc, Steffan T. Nawrocki, PhD, Swapna Thota, MD, Kevin R. Kelly, MD PhD, Bhumika Patel, MD, Cassandra M. Hirsch, BSc, Hetty E. Carraway, MD MBA, Yvonne Parker, Daniel Lindner, Mikkael A. Sekeres, MD MS, Heesun J Rogers, MD PhD, Jaroslaw P. Maciejewski, MD, PhD, FACP, Jennifer S. Carew, PhD

Blood (2016) 128 (22): 4301.

https://doi.org/10.1182/blood.V128.22.4301.4301

Published: 2016

Journal Articles

Development of ROC-325: A Novel Small Molecule Inhibitor of Autophagy with Promising Anti-Leukemic Activity

Steffan T. Nawrocki, PhD, Yingchun Han, MD, Valeria Visconte, PhD, James G Phillips, PhD, Bartlomiej P Przychodzen, MSc, Jaroslaw P Maciejewski, MD PhD FACP, Kevin R. Kelly, MD PhD, Jennifer S. Carew, PhD

Blood (2016) 128 (22): 525.

https://doi.org/10.1182/blood.V128.22.525.525

Published: 2016

Journal Articles

Oncolytic Reovirus Immune Priming: A Phase 1b Study of Reolysin with Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma

Kevin R. Kelly, MD PhD, Kaijin Wu, PhD, Denice Tsao-Wei, Susan Groshen, Timothy Junius Triche, Jr., PhD, Ann Mohrbacher, Grace Chang, MD, Donna Fernando, Imran N Siddiqi, MD PhD, Matt Coffey, George Gill, Amy Lee, Jennifer S. Carew, PhD, Steffan T. Nawrocki, PhD

Blood (2016) 128 (22): 4507.

https://doi.org/10.1182/blood.V128.22.4507.4507

Published: 2016

Journal Articles

Indatuximab Ravtansine (BT062) in Combination with Low-Dose Dexamethasone and Lenalidomide or Pomalidomide: Clinical Activity in Patients with Relapsed / Refractory Multiple Myeloma

Kevin R. Kelly, MD PhD, David S. Siegel, MD PhD, Asher A. Chanan-Khan, MD, George Somlo, MD, Leonard T. Heffner, MD, Sundar Jagannath, MD, Todd Zimmerman, MD, Nikhil C Munshi, MD, Sumit Madan, MD, Ann Mohrbacher, MD, Sagar Lonial, MD FACP, Farima Barmaki-Rad, MD, Markus Rühle, MD, Eva Herrmann, MSc, Andrea Wartenberg-Demand, MD, Thomas Haeder, PhD, Kenneth C. Anderson, MD

Blood (2016) 128 (22): 4486.

https://doi.org/10.1182/blood.V128.22.4486.4486

Published: 2016

NARROW

Pharmacologic Normalization of Altered Transcriptome of SF3B1 Mutant Myeloid Neoplasia

Updated Results from the Venetoclax (Ven) in Combination with Idasanutlin (Idasa) Arm of a Phase 1b Trial in Elderly Patients (Pts) with Relapsed or Refractory (R/R) AML Ineligible for Cytotoxic Chemotherapy

CUL1: Novel Therapeutic Target in Myeloid Neoplasms Harboring -7/Del(7q)

A Pooled Analysis of Relapsed/Refractory Diffuse Large B-Cell Lymphoma Patients Treated with the Dual PI3K and HDAC Inhibitor Fimepinostat (CUDC-907), Including Patients with MYC-Altered Disease

Exploring Disease Biology in Hispanic Versus Non-Hispanic Patients with Diffuse Large B-Cell Lymphoma (DLBCL) to Explain Survival Disparities

Development of a Novel Class of Agents Targeting the RNA-Splicing Machinery in Myeloid Malignancies

Activation of Autophagy in Models of SF3B1 Mutant MDS

Preliminary Results from a Phase Ib Study Evaluating BCL-2 Inhibitor Venetoclax in Combination with MEK Inhibitor Cobimetinib or MDM2 Inhibitor Idasanutlin in Patients with Relapsed or Refractory (R/R) AML

Racial Differences in Disease Characteristics: Understanding Multiple Myeloma in Hispanics

The Presence of Philadelphia Chromosome Does Not Confer Poor Prognosis in Adult Pre-B Acute Lymphoblastic Leukemia in the Tyrosine Kinase Inhibitor Era - a Surveillance, Epidemiology, and End Results Database Analysis

Oncolytic Reovirus Sensitizes Multiple Myeloma Cells to Anti-PD-L1 Therapy

Minimal Residual Disease (MRD) Assessment By Multiparametric Flow Cytometry Is Prognostic for Progression-Free Survival in Phase 1/1b Relapsed/Refractory Acute Myeloid Leukemia (AML) Patients Treated with Idasanutlin MDM2 Antagonist

Persistent Racial/Ethnic Disparities in Outcomes for Multiple Myeloma: A SEER-Database Update

Racial/Ethnic Disparities in NK/T-Cell Non-Hodgkin Lymphomas in the US: A SEER Analysis

A Novel Oncolytic Reovirus Immune Priming Strategy Dramatically Enhances the Efficacy of Anti-PD-L1 Antibody Therapy Against Multiple Myeloma

Targeting Autophagy in Myelodysplastic Syndromes

Genetic and Epigenetic Defects in the Autophagy Machinery in Myelodysplastic Syndromes

Development of ROC-325: A Novel Small Molecule Inhibitor of Autophagy with Promising Anti-Leukemic Activity

Oncolytic Reovirus Immune Priming: A Phase 1b Study of Reolysin with Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma

Indatuximab Ravtansine (BT062) in Combination with Low-Dose Dexamethasone and Lenalidomide or Pomalidomide: Clinical Activity in Patients with Relapsed / Refractory Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only